RankAlpha logo
Back to Rankings

PCRX

Pacira BiosciencesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings bull case is that Pacira now has synchronized revenue growth across EXPAREL, ZILRETTA, and iovera, reiterated full-year guidance, and several 2026 data catalysts that could expand the commercial footprint or validate the HCAd platform. Primary filings also show $202.2 million of cash and investments and management states near-term liquidity is adequate [#10-Q-2026-04-30].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.3.
What can break
At March 31, 2026, Pacira had about $367.7 million of debt, including 2029 converts and a revolving credit facility, while also spending $50.0 million on buybacks in Q1 [#10-Q-2026-04-30].
Momentum
32
Value
70
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $34.00 · Bear $17.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $30.00
Why
Momentum32 · Δ7d -7.2
Value70 · Δ7d +0.3
Sentiment67 · Δ7d +5.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
32
34% active weight
Current posture
7d trendFlat
Δ7d
-7.2
Δ21d
-13.6
Value
70
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.4
Sentiment
67
33% active weight
Current posture
7d trendImproving
Δ7d
+5.2
Δ21d
+7.5
Why this grade

Composite grade B. Momentum 31.9 / Value 69.6 / Sentiment 66.9

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$875.2M
Beta
0.25
Shares Out
43.02M
P/E (TTM)
53.8
P/S (TTM)
1.51
P/FCF (TTM)
8.69
Rev YoY
+6.5%
EPS YoY
+103.9%
Gross Margin
+79.2%
Op Margin
+4.1%
Net Debt
$100.71M
Current Ratio
5.26
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology